ABOUT SAMARITAN PHARMACEUTICALS

Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop. As a drug proves to appear promising we develop it through late-stage preclinical studies to investigational new drug (IND) application and through Phase I/II clinical trials, before costly phase III clinical trials.

Samaritan has partnered SP01A with Pharmaplaz an Irish healthcare development company. Pharmaplaz will be responsible for clinical development, clinical trial costs and manufacturing. Samaritan has also entered into strategic collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Poland, Romania, Slovakia, Syria, Turkey and Yugoslavia and Eastern Europe. We use our expertise to register approved drugs with regulatory agencies in the Country we have acquired the rights for; and then, upon regulatory approval, we distribute, market and sell these products. Currently, we have in-licensed the rights to sell eleven drugs, Amphocil from Three Rivers Pharmaceuticals, Elaprase from Shire Pharmaceuticals, Infasurf from Ony, Inc, and Mepivamol, Methadone, Morphine Sulphate, Naloxone, Naltrexone, and Oramorph from Molteni Pharmaceuticals, and Rapydan from EUSA.